Dexamethasone News and Research

RSS

No added benefit from aflibercept, shows study

For the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG) dealt with the drug aflibercept. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the Institute now examined whether aflibercept (trade name: Eylea) offers an added benefit over the appropriate comparator therapy in visual impairment due to macular oedema following occlusion of the central retinal vein.

8 Jan 2014

First patient enrolled in Otonomy's pivotal Phase 2b study of OTO-104 for Meniere's disease

Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced enrollment of the first patient in its pivotal Phase 2b study of OTO-104 for the reduction of vertigo in patients with unilateral Meniere's disease.

11 Dec 2013

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

Celgene: FIRST trial meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene today announced that data from the FIRST (Frontline Investigation of lenalidomide and dexamethasone vs. standard thalidomide) trial was presented on Sunday 8 December, during the Plenary Scientific Session at the 55th American Society Hematology annual meeting in New Orleans. FIRST (MM-020/IFM 07-01) a phase III, multi-centre study in patients newly diagnosed with multiple myeloma and ineligible for stem cell transplant, included 72 patients from the UK.

11 Dec 2013

Takeda presents clinical study results of oral proteasome inhibitor MLN9708 in multiple myeloma patients

Takeda Pharmaceutical Company Limited today announced final Phase 1 and preliminary Phase 2 results of a study combining oral investigational MLN9708 administered twice a week with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

10 Dec 2013

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase inhibitors for enhanced therapeutic outcomes, today announced that positive interim clinical data from the two proof-of-concept clinical trials with selective HDAC6 inhibitor, ricolinostat (ACY-1215), were presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, LA.

9 Dec 2013

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

NOXXON Pharma disclosed interim data from two independent clinical phase IIa studies of the anti-CXCL12/SDF-1 Spiegelmer olaptesed pegol (NOX-A12) at the 55th annual meeting of the American Society of Hematology in New Orleans, LA, USA from 7-10 December 2013.

9 Dec 2013

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

4 Dec 2013

Scientists to develop on-demand drug-delivery system for pain management in osteoarthritis patients

Scientists are reporting development of a squishy gel that when compressed - like at a painful knee joint - releases anti-inflammatory medicine. The new material could someday deliver medications when and where osteoarthritis patients need it most. Their study appears in the ACS journal Biomacromolecules.

8 Nov 2013

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2014.

31 Oct 2013

$Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma$

Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma

The Lancet Oncology published this week findings from a study, which showed that the new oral therapy IMNOVID®▼ (pomalidomide), used in combination with low-dose dexamethasone demonstrated a significant survival advantage over high-dose dexamethasone alone, in patients with relapsed and refractory multiple myeloma (rrMM).1

5 Sep 2013

Oncopeptides launches phase II study to determine efficacy of melflufen in treatement of multiple myeloma

Oncopeptides AB, a company working to enhance oncology therapies, today announced that the first patient has been dosed as part of a Phase II study in multiple myeloma patients with its drug candidate melflufen (previously called J1).

21 Aug 2013

Celgene's pomalidomide gets approval in UK for multiple myeloma

Celgene confirmed today that Pomalidomide Celgene▼ (pomalidomide), a new oral blood cancer therapy, has been granted Marketing Authorisation by the European Medicines Agency and is now available in the UK and Ireland.

9 Aug 2013

Janssen receives EC approval to use VELCADE as induction therapy in patients with multiple myeloma

Janssen-Cilag International NV announced today that the European Commission has approved the use of VELCADE (bortezomib) as induction therapy (a first therapeutic option) in combination with dexamethasone or thalidomide and dexamethasone. This licence extension will apply to adult patients with previously-untreated multiple myeloma who are eligible for high-dose chemotherapy with haematological stem cell transplantation.

8 Aug 2013

Discovery may help explain how anti-inflammatory steroid drugs work

A gene long presumed dead comes to life under the full moon of inflammation, Stanford University School of Medicine scientists have found.

23 Jul 2013

Bacillus-derived Hyaluronic acid from Novozymes Biopharma, Hyasis®, increases in vitro drug release time from under 10 minutes to approximately 15 hours

An investigation undertaken by Novozymes Biopharma DK has shown that when the corticosteroid dexamethasone is formulated in a cross-linked Hyaluronic acid (HA) hydrogel, the drug’s in vitro release time increases from under 10 minutes to approximately 15 hours. In addition, the in vivo half-life of dexamethasone is shown to plateau with stable dexamethasone concentration up to four hours after injection.

22 Jul 2013

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.

11 Jul 2013

Chemical hormone released due to stress can trigger mechanism for late onset of Alzheimer's disease

A chemical hormone released in the body as a reaction to stress could be a key trigger of the mechanism for the late onset of Alzheimer's disease, according to a study by researchers at Temple University.

20 Jun 2013

Takeda begins MLN9708 phase 3 clinical trial in newly diagnosed myeloma patients

Takeda Pharmaceutical Company Limited today announced the initiation of an international phase 3 clinical trial evaluating once a week MLN9708 in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma who are not candidates for transplant.

24 May 2013

Study shows promising benefit of combination therapy in CRPC patients

Multi-peptide vaccination therapy combined with the low-dose steroid drug dexamethasone shows promise in treating chemotherapy-naive castration resistant prostate cancer (CRPC) patients.

16 Mar 2013

Dexamethasone News and Research

No added benefit from aflibercept, shows study

First patient enrolled in Otonomy's pivotal Phase 2b study of OTO-104 for Meniere's disease

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene: FIRST trial meets primary endpoint in patients newly diagnosed with multiple myeloma

Takeda presents clinical study results of oral proteasome inhibitor MLN9708 in multiple myeloma patients

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Scientists to develop on-demand drug-delivery system for pain management in osteoarthritis patients

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma

Oncopeptides launches phase II study to determine efficacy of melflufen in treatement of multiple myeloma

Celgene's pomalidomide gets approval in UK for multiple myeloma

Janssen receives EC approval to use VELCADE as induction therapy in patients with multiple myeloma

Discovery may help explain how anti-inflammatory steroid drugs work

Bacillus-derived Hyaluronic acid from Novozymes Biopharma, Hyasis®, increases in vitro drug release time from under 10 minutes to approximately 15 hours

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Chemical hormone released due to stress can trigger mechanism for late onset of Alzheimer's disease

Takeda begins MLN9708 phase 3 clinical trial in newly diagnosed myeloma patients

Study shows promising benefit of combination therapy in CRPC patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News